BioCardia Announces Pause in Enrollment for Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia Announces Pause in Enrollment for Phase III CardiAMP Cell Therapy Heart Failure Trial SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease treatment, has received a recommendation from the independent Data Safety Monitoring Board (DSMB) to temporarily pause new..